Last reviewed · How we verify
glargine basal insulin and glulisine prandial insulin
glargine basal insulin and glulisine prandial insulin is a Small molecule drug developed by Emory University. It is currently FDA-approved. Also known as: Lantus inuslin, Apidra insulin.
At a glance
| Generic name | glargine basal insulin and glulisine prandial insulin |
|---|---|
| Also known as | Lantus inuslin, Apidra insulin |
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
- Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) (PHASE4)
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus (PHASE2)
- Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM (NA)
- Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day (PHASE4)
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus (PHASE2)
- Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glargine basal insulin and glulisine prandial insulin CI brief — competitive landscape report
- glargine basal insulin and glulisine prandial insulin updates RSS · CI watch RSS
- Emory University portfolio CI
Frequently asked questions about glargine basal insulin and glulisine prandial insulin
What is glargine basal insulin and glulisine prandial insulin?
glargine basal insulin and glulisine prandial insulin is a Small molecule drug developed by Emory University.
Who makes glargine basal insulin and glulisine prandial insulin?
glargine basal insulin and glulisine prandial insulin is developed and marketed by Emory University (see full Emory University pipeline at /company/emory-university).
Is glargine basal insulin and glulisine prandial insulin also known as anything else?
glargine basal insulin and glulisine prandial insulin is also known as Lantus inuslin, Apidra insulin.
What development phase is glargine basal insulin and glulisine prandial insulin in?
glargine basal insulin and glulisine prandial insulin is FDA-approved (marketed).
Related
- Manufacturer: Emory University — full pipeline
- Also known as: Lantus inuslin, Apidra insulin
- Compare: glargine basal insulin and glulisine prandial insulin vs similar drugs
- Pricing: glargine basal insulin and glulisine prandial insulin cost, discount & access